RNS Number : 7341I
  Lombard Medical Technologies PLC
  24 November 2008
   

    Press information 

    Lombard Medical Technologies PLC
    ("Lombard Medical" or the "Company")

    US Trial Update and Further Cost Cutting Measures


    London, 24 November 2008 - At an international endovascular symposium held in New York last week, Dr Fillinger, the Principal
Investigator of the US clinical trial for Aorfix* in the treatment of abdominal aortic aneurysms (AAAs) reported positive data on the first
21 patients after 1/� year's follow up and on his personal experience of 13 cases in the 160 patient trial.  

    Dr Fillinger stated that this data showed the Aorfix* stent graft had treated the most challenging anatomy ever attempted in a US
clinical trial and had given results which were equivalent to approved devices used in straightforward cases. He commented that the 105th
case will take place on November 21st and that recruitment into the trial had grown exponentially. Dr Fillinger listed 38 US hospitals
taking part in the study and 3 Canadian sites which recently received approval from Health Canada to join the Aorfix* study.

    Separately the Company announces that it has received a very positive response from a voluntary proposal to staff designed to
temporarily reduce payroll costs by up to 20% either through a reduction in working hours or the deferral of part of the employee's pay
until after the Company has raised further funds.


    Brian Howlett, Lombard Medical's Chief Executive Officer, said:

    "The data presented by Dr Fillinger is in line with that reported in the most recent PMAs from competitor products even though many of
the cases have been in tortuous anatomy that cannot be treated with the current range of licensed products. At a time when the FDA is
becoming increasingly critical of the use of medical devices outside of their indication for use, we see the unique label claim sought for
Aorfix* in high-angle-neck aneurysms (up to 90�) as being of great value.

    "We remain grateful to all our staff for their continued support in recent months. As previously announced, the changes are part of a
broader strategy to reduce costs while we continue to pursue sources of finance." 


    - ENDS -

    Enquiries:

 Lombard Medical Technologies PLC                    Tel: +44 (0) 1235 750 800
 Simon Neathercoat, Non-Executive Chairman
 Brian Howlett, Chief Executive Officer
 Tim Hall, Finance Director

 Financial Dynamics                                  Tel: +44 (0) 20 7831 3113
 David Yates / Susan Quigley
                 
 Nomura Code Securities Limited                      Tel: +44 (0) 20 7776 1200
 Juliet Thompson / Richard Potts


    About Lombard Medical
    Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment
of vascular disease. The Company's lead product, Aorfix*, is an endovascular stent graft for the treatment of abdominal aortic aneurysms
(AAAs), a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Approximately 1.7 million people have AAAs
in the US where it is the 13th largest cause of death. The market for endovascular stent grafts for the treatment of AAA is currently worth
over $600 million and is expected to grow to around a $1 billion by 2010. Aorfix* is currently being commercialised in the EU, with a
pivotal clinical trial ongoing in the USA.  

    The Company's Polymer Coatings Division has developed a novel hydrophilic surface treatment to reduce friction on catheters called
GlideMax*, which is available for licensing, and is using its polymer coating technology in a number of research collaborations developing
novel products for the $5 billion drug-eluting stent market.

    The Company is headquartered in Oxfordshire, with operations in Yorkshire, Ayrshire and Boston, USA.

    Further background on the Company can be found at www.lombardmedical.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCPUGUAGUPRGMW
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lombard Medical Technologies Charts.